LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, " ...

Core Viewpoint - Niagen Bioscience, Inc. has acquired a comprehensive portfolio of patents related to nicotinamide riboside (NR) from Queen's University Belfast, enhancing its leadership in NAD+ precursor intellectual property [1] Group 1: Company Developments - The acquisition strengthens Niagen's long-standing ownership position in the NAD+ precursor market [1] - The focus of the company is on the science of healthy aging, positioning it as a global authority in NAD+ [1] Group 2: Industry Implications - The acquisition of these patents may lead to increased innovation and product development in the field of healthy aging and NAD+ research [1] - This move could potentially enhance the competitive landscape within the biotech industry, particularly in the area of aging-related health solutions [1]